Q419/FY19 US Joint Fluid Market Recap: Stronger Demand for Single Injection

Overall, 2019 was a good recovery year for the US Joint Fluid market with Single-injection treatment options at the helm

For Q419, revenue in the US Joint Fluid market was up, recovering fairly well from a year ago according to SmartTRAK Financial Dashboard. Aggregate growth for the quarter was attributable to a double-digit revenue growth in single injection. Stronger demand and heavy product push in that segment, especially at year-end, was offset to a certain extent by revenue declines in 3- and 5-injections. 

Among the many topics covered in the comprehensive Q419 US Joint Fluid Market Recap* are:

• Comprehensive Market Overview
• Single-Injection: Reigning as King of The Hill
• 3-Injection: The Victors and The Vanquished
• 5-Injection – Downward Spiral With No End In Site
• 2020: A Look Ahead

For FY19, the US Joint Fluid market appears to have bounced back somewhat from a rough year in 2018 but not quite back to the level of performance seen in 2017. According to SmartTRAK Financial Dashboard, revenue finished at $, up YoY and slightly above forecast. Though marginal, the overall revenue growth of the US Joint Fluid market for FY19 is attributed to a strong year-end push in product placement and to and to several competitors securing preferred formulary status with major commercial health insurance providers, while others simply used smart contracting.

Read the entire Q419 US Joint Fluid Market Recap including news, data, charts, company revenues and analysis*...